Please assess the completion status of the following clinical trial:

Trial Title: Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the Medical Withdrawal Unit at the Centre for Addiction and Mental Health for medically assisted withdrawal from benzodiazepines, zopiclone and/or zolpidem~* Willing and capable to give written informed consent~Exclusion Criteria:~* Patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.~* Pregnant or nursing women~* Renal impairment (creatinine clearance less than 60ml/min)~* History of angioedema, or taking drugs associated with angioedema (e.g., ACE-inhibitors).~* Currently taking pregabalin or gabapentin~* Currently taking thiazolidinedione antidiabetic agents (e.g., rosiglitazone, pioglitazone)~* Previous history of pregabalin or gabapentin abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).